Global Epidemiology of Mucormycosis associated with post Covid-19 complication

COVID-19, which is caused by the SARS-CoV-2 virus, first appeared in Wuhan, China in the year 2019. It has been linked to a variety of fungal and bacterial illnesses that are opportunistic. There have been several reports of fungal infections following COVID-19. Recently, several cases of mucormycosis have been reported worldwide, particularly in India. Mucormycosis (zygomycosis) is a fungal infection caused by members of the Mucorales and Zygiomycotic species with inhalation of fungal spores as the mechanism of infection. Poorly controlled debilitating diseases (such as diabetes), immunosuppression and trauma are all risk factors. The rise in cases of mucormycosis is a result of corticosteroid application in patients having COVID-19 complications. In diabetes mellitus, the rhinocerebral form of mucormycosis is most commonly seen whereas pulmonary mucormycosis has been seen in patients having hematological malignancy or undergoing blood/organ transplantation. However, in this mini-review, we are emphasizing the role of mucormycosis during COVID-19 infection, encompassing the types of mucormycosis, their diagnosis and treatment.